Anti-IL-36R antibodies, potentially useful for the treatment of psoriasis: a patent evaluation of WO2013074569.
The IL-36 family of cytokines and receptors seems to play a role in the pathogenesis of both pustular psoriasis, and the much more common variant, plaque-type psoriasis. Human skin biopsies from patients with psoriasis show overexpression of IL-36 and mice that lack the inhibitory IL-36 receptor (IL-36Ra) antagonist develop psoriasis, suggesting that signaling through the IL-36R may drive the skin lesions of psoriasis. Currently, no drugs targeting IL-36 are used in the treatment of psoriasis. The patent WO2013074569 describes an antibody to the IL-36R that is proposed as a potential therapy for psoriasis.
University of Pittsburgh School of Medicine , 5th Floor, Pittsburgh, PA 15213 , USA.
Joel
J
Wolf
Laura Korb
LK
Ferris
D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D010330:Patents as Topic; D011565:Psoriasis / Q000188:drug therapy*; D018123:Receptors, Interleukin / Q000037:antagonists & inhibitors*
D061067:Antibodies, Monoclonal, Humanized; D018123:Receptors, Interleukin; C571244:interleukin-36 receptor, human